{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:33:02Z","timestamp":1790173982461,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite the recent substantial improvement of clinical outcome in mantle cell lymphoma (MCL), resistance to immunochemotherapy and common relapses are challenges for long-term tumor control. The assessment of minimal residual disease (MRD) by real-time quantitative polymerase chain reaction has emerged as a widely feasible and standardized tool for direct assessment of therapy-induced reduction of tumor burden and regrowth after cytotoxic treatment in MCL, with much improved sensitivity compared with conventional staging procedures. Several studies have shown that intensification of initial treatment, which has resulted in improved clinical outcome, is immediately reflected in higher molecular remission rates; they have also shown that high-dose consolidation might not be able to compensate for less intensive induction regimens. Persistence or reappearance of MRD in clinical remission proved to be highly predictive for imminent clinical relapse associated with shorter overall survival. Therefore, the investigation of novel MRD-guided treatment strategies aimed at early eradication of MRD and pre-emptive treatment of molecular relapse seems warranted. Furthermore, the integration of MRD assessment into clinical response criteria could result in a more specific and potentially earlier end point for treatment efficacy. New technical developments such as high-throughput sequencing will further enhance the wide applicability of MRD detection in MCL.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.437","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"437-445","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment"],"prefix":"10.1182","volume":"2016","author":[{"given":"Eva","family":"Hoster","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Munich, and Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-University Munich, Munich, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[{"name":"Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2019111703083515100_B1","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111703083515100_B2","author":"Hoster","year":"2014"},{"issue":"7","key":"2019111703083515100_B3","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"2019111703083515100_B4","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high-dose cytarabine containing myeloablative regimen and autologous stem cell transplantation versus 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and autologous stem cell transplantation in patients <65years (MCL Younger): a randomised, open-label, phase 3 trial of the European MCL Network","author":"Hermine","journal-title":"Lancet"},{"issue":"2","key":"2019111703083515100_B5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur J Haematol"},{"issue":"7","key":"2019111703083515100_B6","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"9873","key":"2019111703083515100_B7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"2019111703083515100_B8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111703083515100_B9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111703083515100_B10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703083515100_B11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"B\u00f6ttcher","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2019111703083515100_B12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111703083515100_B13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cytob.21210","article-title":"Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach","volume":"88","author":"Chovancov\u00e1","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"2019111703083515100_B14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Semin Hematol"},{"issue":"7","key":"2019111703083515100_B15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0301-472X(02)00807-X","article-title":"Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1\/JH rearrangements in mantle cell lymphoma","volume":"30","author":"Andersen","year":"2002","journal-title":"Exp Hematol"},{"issue":"6","key":"2019111703083515100_B16","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"issue":"16","key":"2019111703083515100_B17","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111703083515100_B18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"134","key":"2019111703083515100_B19","doi-asserted-by":"crossref","first-page":"134ra63","DOI":"10.1126\/scitranslmed.3003656","article-title":"High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia","volume":"4","author":"Wu","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6","key":"2019111703083515100_B20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"2019111703083515100_B21","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2019111703083515100_B22","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"2019111703083515100_B23","author":"Pott"},{"key":"2019111703083515100_B24","author":"Pott","year":"2010"},{"issue":"19","key":"2019111703083515100_B25","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"key":"2019111703083515100_B26","article-title":"Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4","author":"Albertsson-Lindblad","journal-title":"Blood"},{"issue":"1","key":"2019111703083515100_B27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111703083515100_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.338.338","article-title":"Predictive power of early, sequential MRD monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; interim results from the LyMa-MRD Project, conducted on behalf of the Lysa Group","volume":"126","author":"Callanan","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111703083515100_B29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"issue":"23","key":"2019111703083515100_B30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.337.337","article-title":"Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (Alliance) 50403","volume":"126","author":"Kaplan","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111703083515100_B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3002.3002","article-title":"Minimal residual disease (MRD) status following induction chemo-immunotherapy predicts progression-free survival in mantle cell lymphoma (MCL): CALGB 50403 (Alliance)","volume":"122","author":"Fulton","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111703083515100_B32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111703083515100_B33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111703083515100_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.147.147","article-title":"MRD eradication should be the therapeutic goal in mantle cell lymphoma and may enable tailored treatment approaches: results of the intergroup trials of the European MCL Network","volume":"124","author":"Pott","year":"2014","journal-title":"Blood"},{"issue":"27","key":"2019111703083515100_B35","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111703083515100_B36","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111703083515100_B37","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO)","volume":"93","author":"Kr\u00fcger","year":"2014","journal-title":"Ann Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/437\/1252316\/hem088375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/437\/1252316\/hem088375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:08:52Z","timestamp":1573978132000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/437\/21145\/Minimal-residual-disease-in-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.437","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}